Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Markets Drive Consumer Health Growth, Pose Challenges

This article was originally published in PharmAsia News

Executive Summary

Developing markets account for 50% of the global self-care product sales, but close to 100% of the sector’s growth, according to market research firm IMS Health. This picture will continue as OTC drugs and dietary supplements have a bigger health care role in developing countries than in developed markets.

You may also be interested in...

GSK Hones OTCs As “Sharp End” Of Consumer Products Business

Glaxo’s OTC business is “the very best end of consumer goods as opposed to being a poor relation of pharmaceuticals,” says Emma Walmsley, GSK Consumer Healthcare president.

Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch

FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.

Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo

Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts